CARIBOU BIOSCIENCES INC (CRBU)
Health Care · biotechnology · NASDAQ
A clinical-stage CRISPR genome-editing company developing off-the-shelf allogeneic CAR-T cell therapies for hematologic cancers.
What CARIBOU BIOSCIENCES INC does
Caribou Biosciences is a clinical-stage biopharmaceutical company focused on developing allogeneic "off-the-shelf" CAR-T cell therapies for hematologic malignancies. Its proprietary chRDNA (CRISPR hybrid RNA-DNA) platform enables precise genome editing to create therapies that are engineered for enhanced activity through strategies like checkpoint disruption and immune cloaking. The company is currently advancing lead candidates targeting CD19 and BCMA in phase 1 clinical trials.
Recent developments
In May 2026, the company reached FDA alignment on the design for its planned pivotal phase 3 clinical trial (ANTLER-3) for vispa-cel. Additionally, updated phase 1 data presented at EHA 2026 for both vispa-cel and CB-011 demonstrated sustained efficacy and durable responses in their respective patient populations.
From CARIBOU BIOSCIENCES INC's filing of 2026-08-13.
Themes: CRISPR genome editing, allogeneic CAR-T cell therapy, cancer immunotherapy, hematologic oncology
Fundamentals
- Price$0.4812 as of 2026-10-08 close
- Market cap$52M as of 2026-08-07 (share count; price 2026-10-08)
- 1-year return-82.0% 2025-10-08 close $2.68 → 2026-10-08 close $0.4812
- P/En/a negative earnings
- Net margin-1327.4% FY2025, SEC XBRL
- ROE-121.2% FY2025, SEC XBRL
- Debt / equity0.00 as of 2026-09-03
- Revenue growth (YoY)+13.0% as of 2026-09-03
- Revenue CAGR (3y)-7.0% SEC XBRL
- Beta1.79 as of 2026-09-03
- Last reported earnings2026-08-13 SEC EDGAR Form 8-K (Item 2.02)
How CRBU compares in its sector
- net profit marginbottom 10% 430 covered Health Care peers, as of 2026-09-03
- operating marginbottom 10% 417 covered Health Care peers, as of 2026-09-03
- return on equitybottom 25% 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRbottom 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How CARIBOU BIOSCIENCES INC looks technically
CARIBOU BIOSCIENCES INC (CRBU) is trading 72.0% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 64 trading days ago — a "death cross", a bearish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 42, with sellers in control. Momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 11, in oversold territory (below 30). MACD, a trend-momentum gauge, turned bearish about 3 trading days ago (its momentum flipped negative). It just made a new 20-day low, breaking below its recent trading range. It is 86.4% below its highest point of the past year. Trading volume is running unusually high — about 7.7× its 30-day average, a sign of heightened interest.
Trend
8
| Distance from the 200-day | it is trading 72.0% below its 200-day average, the long-term trend line — a long-term downtrend | -72.0% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $1.43 | $1.43 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $1.72 | $1.72 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 44 calendar days ago — the swings before that are what the structure reading is measured on | 44 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 1.76. It is the only labelling that fits, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 64 trading days ago — a "death cross", a bearish long-term signal | 64 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 42, with sellers in control | 41.7 |
Momentum
3
| 14-day RSI | momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 11, in oversold territory (below 30) | 11.1 |
|---|---|---|
| Position in its 14-day range | it is trading right at the bottom of its 14-day range ($0.4503 to $1.36) — its "stochastic" reading is 3 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 3.4 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 3 trading days ago (its momentum flipped negative) | 3 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $3.54 | $3.54 |
|---|---|---|
| From the 52-week high | it is 86.4% below its 52-week high (its highest price of the past year) | -86.4% |
| Above the 52-week low | it is 6.9% above its 52-week low (its lowest price of the past year) | +6.9% |
| Below the 52-week high | it is 86.4% below its highest point of the past year | 86.4% |
| Since a 20-day breakout | it just made a new 20-day low, breaking below its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day low, breaking below its recent trading range | 1 session |
| All-time high | its highest closing price on record is $32.64 (set on 2021-09-07) | $32.64 |
| Given back of the 52-week move | over the past year its closes ranged ($0.4812 to $2.84), and it has recovered essentially none of its fall from last year’s high — 0% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $1.94 to $2.01. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 0.0% |
| From the all-time high | it is 98.5% below its all-time high | -98.5% |
| Nearest price level | it is trading 51.7% below a resistance level at $0.7301 — a price it turned at twice since 2025-04-28, most recently on 2025-05-08. Since 2024-10-08 it has 0 such levels below the current price and 14 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +51.7% |
| All-time low | its lowest closing price on record is $0.4503 (set on 2026-10-08) | $0.4503 |
| Above the all-time low | it is 6.9% above its all-time low | +6.9% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 99% of the past ~6 months) | 99th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.1064 between its high and its low — about 22.1% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.1064 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $0.75 and $1.62 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $0.75 – $1.19 – $1.62 |
| Typical daily range (% of price) | its price moves about 22.1% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 22.1% |
| Stretch from the 200-day average | it is trading 11.6 daily ranges below its 200-day average price (72.0% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 11.6 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is running unusually high — about 7.7× its 30-day average, a sign of heightened interest | 7.73× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 42.7% since the prior reading | -42.6% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Price gaps
3
| Gap at the open | it opened on 2026-10-08 3.8% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | -3.8% |
|---|---|---|
| Open gap | it gapped 3.8% below the previous close today and has not traded back through the level it left behind at 0.62 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -3.8% |
| Gap filled | a 3.1% gap up opened on 2026-09-30 has been "filled" 5 sessions ago — price traded back through the level the gap left behind, and it took 1 session to close | 5 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 4 sessions in a row, a -60.56% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 4 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 69.8 percentage points (the stock lost 68.8% while the market gained 1.0%) | -69.8% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 79.0 percentage points (the stock lost 75.2% while the market gained 3.8%) | -79.0% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 92.8 percentage points (the stock lost 75.3% while the market gained 17.5%) | -92.8% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 97.0 percentage points (the stock lost 82.0% while the market gained 15.0%) | -97.0% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: its RSI momentum gauge is oversold (a beaten-down reading), near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 7 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, a fresh 20-day low, MACD momentum is negative, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 7 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 70% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 31.5% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -70.2% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 69% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $1.56 — a volume-weighted average of daily closes over 190 sessions, not a true tick-by-tick VWAP. | -69.2% |
|---|---|---|
| Vs the average paid since it last reported | the price is 49% below the average price paid since it last reported on 2026-08-13 (its 10-Q), so the typical buyer over that stretch is under water. That average is $0.9419 — a volume-weighted average of daily closes over 40 sessions, not a true tick-by-tick VWAP. | -48.9% |
Price levels it has turned at before
CRBU last closed at $0.4812 on 2026-10-08. Since 2024-10-08 it has turned at 0 prices below its last close and 14 above; the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $0.7301 | Resistance | 51.7% above the last close | turned there twice · 2025-04-28 to 2025-05-08 |
| $0.9057 | Resistance | 88.2% above the last close | turned there twice · 2025-04-23 to 2025-05-02 |
| $1.22 | Resistance | 152.5% above the last close | turned there twice · 2025-05-28 to 2025-07-01 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $1.76.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
This reading has stood for 27 trading days, since 2026-09-01.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Oversold (14-day RSI below 30) · Pulled back from the 12-month high · Unusually heavy trading volume · Broke down to a new 20-day low · MACD just crossed bearish (12/26/9) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low · volume and relative volume
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (2.00 mean, 1=Strong Buy…5=Strong Sell) — 5 analysts
- Mean price target$6.80 range $1.00 – $13.00; median $8.00
Analyst estimates, as of 2026-10-08. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for CRBU
- Consensus EPS estimate-$0.2667 next reporting period, as of 2026-10-08
- Estimate change, 30 days+$0.03583 from -$0.3025, on 2026-09-03, 35-day window
- Readings revised upward14% of 7 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["High degree of financial risk due to clinical-stage status and history of operating losses.","Dependence on the success of the chRDNA platform and the ability to successfully navigate pivotal clinical trials.","Competitive landscape in CAR-T and cell therapy, including established autologous alternatives and other allogeneic approaches."]
What changed in the latest 10-Q
AI-assisted comparison of CRBU's 10-Q filed 2026-08-13 against the prior one filed 2026-05-07.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (filed 2026-08-13) states the Form 10-Q is for the fiscal quarter ended June 30, 2026.
- Newer filing (filed 2026-08-13) specifies vispa-cel has been evaluated in ANTLER as a multicenter, open-label phase 1 clinical trial.
- Newer filing (filed 2026-08-13) adds that the ANTLER phase 1 clinical trial is multicenter and open-label for CB-011's CaMMouflage trial as well.
- Newer filing (filed 2026-08-13) adds the announcement date of May 7, 2026 for reaching alignment with the FDA on ANTLER-3 design.
- Newer filing (filed 2026-08-13) adds detailed ANTLER-3 trial design specifics: approximately 250 CD19-naïve 2L LBCL patients, comparator arm options (R-GemOx; Pola-RGO; or tafasitamab and lenalidomide), crossover after progressive disease, primary endpoint of PFS, and clinical trial sites in the United States and globally.
- Newer filing (filed 2026-08-13) adds the announcement date of June 11, 2026 regarding 85 patients treated in ANTLER phase 1.
- Newer filing (filed 2026-08-13) adds new efficacy and safety data as of March 6, 2026 data cutoff for a 27-patient subgroup, including 82% ORR, 67% CR rate, 17.1-month median PFS, no GvHD, no grade 3+ ICANS, one grade 3+ CRS, six grade 3+ infections, five grade 3+ prolonged cytopenias, one grade 3+ IEC-HS, one vispa-cel-related death due to IEC-HS, and one possibly related death due to progressive multifocal leukoencephalopathy.
- Newer filing (filed 2026-08-13) adds text stating CB-011 is the first clinical-stage allogeneic CAR-T cell therapy incorporating an immune cloaking approach.
- Removed:
- Older filing (filed 2026-05-07) states the Form 10-Q is for the fiscal quarter ended March 31, 2026.
- Older filing (filed 2026-05-07) describes vispa-cel as having been evaluated in patients with r/r B-NHL in the ANTLER phase 1 trial without specifying it as multicenter or open-label.
- Older filing (filed 2026-05-07) describes CB-011 as being evaluated in patients with r/r MM in the CaMMouflage phase 1 trial without specifying it as multicenter or open-label.
- Older filing (filed 2026-05-07) refers to expectations about 'our phase 3 pivotal trial design for vispa-cel' rather than specifically naming ANTLER-3.
- Older filing (filed 2026-05-07) contains the November 3, 2025 announcement regarding 84 patients enrolled as of September 2, 2025 safety data cutoff and selection of the RP2D.
- Older filing (filed 2026-05-07) contains a paragraph on leveraging a clinical data set of more than 140 patients dosed and identifying key factors for an optimized vispa-cel profile, including donor age and partial HLA matching.
- Older filing (filed 2026-05-07) contains the 35-patient optimized profile cohort data as of September 2, 2025 (84 patients treated; 35 CD19-naïve LBCL patients) and September 29, 2025 efficacy data cutoff (86% ORR, 63% CR, 53% PFS at 12 months, median follow up 11.8 months).
- Older filing (filed 2026-05-07) contains detailed safety data for all 84 patients as of September 2, 2025: thrombocytopenia (62%), CRS (55%), anemia (52%), neutropenia (39%), hypokalemia (26%), leukopenia (26%), and optimized profile cohort safety (no GvHD, no grade 3+ ICANS, 1% grade 3+ CRS, 28% prolonged cytopenias).
- Older filing (filed 2026-05-07) describes ANTLER-3 as a planned randomized, controlled pivotal phase 3 clinical trial in approximately 250 2L LBCL CD19-naïve patients without the detailed comparator arm, crossover, endpoint, and site information present in the newer filing.
- Older filing (filed 2026-05-07) describes the study arm as receiving a single dose of vispa-cel at the RP2D, while the newer filing specifies the dose as 80x10^6 viable CAR-T cells.
- Reworded:
- Newer filing (filed 2026-08-13) defines vispa-cel as 'vispacabtagene regedleucel ("vispa-cel," formerly CB-010)' and uses 'Vispa-cel' as the bullet point heading; older filing (filed 2026-05-07) uses 'Vispacabtagene regedleucel ("vispa-cel," formerly CB-010)' as the bullet point heading.
- Newer filing (filed 2026-08-13) describes the ANTLER trial as 'multicenter, open-label ANTLER phase 1 clinical trial,' whereas the older filing (filed 2026-05-07) describes it simply as 'ANTLER phase 1 clinical trial.'
- Newer filing (filed 2026-08-13) describes the CaMMouflage trial as 'multicenter, open-label CaMMouflage phase 1 clinical trial,' whereas the older filing (filed 2026-05-07) describes it as 'CaMMouflage phase 1 clinical trial.'
- Newer filing (filed 2026-08-13) states the ANTLER-3 dosing regimen as 'cyclophosphamide at 60 mg/kg/day for two days and fludarabine at 25 mg/m²/day for five days,' while the older filing (filed 2026-05-07) states '60 mg/kg/day for two days of cyclophosphamide and 25 mg/m2/day for five days of fludarabine.'
- Newer filing (filed 2026-08-13) describes patients in the comparator arm as receiving 'an investigator's choice of a standard-of-care regimen' with specific named regimens; the older filing (filed 2026-05-07) does not describe a comparator arm in the excerpt provided.
- Notes:
- The older filing excerpt ends mid-sentence ('Patients randomized to the study arm would receive a single dose of vispa-cel at the RP2D following'), so some content in the older filing may be truncated and not fully comparable.
- The newer filing excerpt is also truncated at the end ('To our knowledge, CB-011 is the first clinical-stage allogeneic CAR-T cell therapy incorporating an immune cloaking approach that'), so additional content beyond the excerpt is not assessed.
- This comparison covers only the provided MD&A excerpts, not the full MD&A sections of either filing.
Risk Factors
- Added:
- In the filing dated 2026-08-13, Item 5 states that during the quarter ended June 30, 2026, none of the directors or officers adopted, modified or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement.
- In the filing dated 2026-08-13, Item 2 heading for unregistered sales references the three months ended June 30, 2026.
- Removed:
- In the filing dated 2026-05-07, Item 2 heading for unregistered sales references the three months ended March 31, 2026.
- In the filing dated 2026-05-07, Item 5 disclosed that Tim Kelly, M.B.A., chief technology officer, entered into a Rule 10b5-1 trading arrangement on February 25, 2026, including a description of the RSU Sell-to-Cover Instruction arrangement.
- In the filing dated 2026-05-07, Item 5 stated that except for the arrangement described, no other Section 16 officer or director adopted or terminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement during the quarter ended March 31, 2026.
- Reworded:
- The Item 5 heading changed from 'Item 5. Other Information' with a 'Rule 10b5-1 Trading Arrangements' subheading in the filing dated 2026-05-07 to 'Item 5. Other Information.' followed directly by the disclosure in the filing dated 2026-08-13.
- Signature page dates changed from May 7, 2026 in the filing dated 2026-05-07 to August 13, 2026 in the filing dated 2026-08-13.
- Notes:
- Both provided texts may include content beyond the Risk Factors section because the excerpts continue into subsequent Items and exhibits.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
Most recent open-market transaction: 2026-02-25. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about CRBU's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding CRBU as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 13,345,047
- Reported value $23,487,281
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 5 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about CRBU's institutional holders → See what each manager we track holds →
Short interest (FINRA)
CRBU had 12,978,605 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
CRBU had 12.1% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 9.49 days to cover at the same settlement.
- Reported short interest (shares) 12,978,605
- Short interest (% of shares outstanding) 12.1%
- Prior settlement (shares) 12,501,320
- Reported change 3.82%
- Days to cover (reported) 9.49
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Bristol Myers Squibb (BMY)
- Gilead Sciences (GILD)
- Novartis (NVS)
- Johnson & Johnson (JNJ)
- Intellia Therapeutics (NTLA)
- CRISPR Therapeutics (CRSP)
- Editas Medicine (EDIT)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare CRBU vs…
Frequently asked questions
What does CARIBOU BIOSCIENCES INC (CRBU) do?
Caribou Biosciences is a clinical-stage biopharmaceutical company focused on developing allogeneic "off-the-shelf" CAR-T cell therapies for hematologic malignancies. Its proprietary chRDNA (CRISPR hybrid RNA-DNA) platform enables precise genome editing to create therapies that are engineered for enhanced activity through strategies like checkpoint disruption and immune cloaking. The company is currently advancing lead candidates targeting CD19 and BCMA in phase 1 clinical trials.
What sector is CARIBOU BIOSCIENCES INC (CRBU) in?
CARIBOU BIOSCIENCES INC (CRBU) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are CARIBOU BIOSCIENCES INC's (CRBU) competitors?
Notable peers of CARIBOU BIOSCIENCES INC (CRBU) include Bristol Myers Squibb, Gilead Sciences, Novartis, Johnson & Johnson and Intellia Therapeutics. This peer set is informational only — not financial advice.
Is CARIBOU BIOSCIENCES INC (CRBU) overbought or oversold right now?
CARIBOU BIOSCIENCES INC (CRBU) is currently in oversold territory (its 14-day RSI is 11, below 30) (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on CRBU come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.